Bullish & Foolish
Full GLSI fundamentals All 466 on the Survival Watch

GLSIGREENWICH LIFESCIENCES, INC.

Is Greenwich Lifesciences struggling financially?

Yes, by its own account. Greenwich Lifesciences told the SEC on 4 Jun 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Jun 2026

11/100

Critical

Cries for help

  • Needs to raise money

    We will continue to incur net losses for the foreseeable future. We will require additional capital to meet our long-term operating requirements.

    Form 10-K, filed 1 Jun 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$244.7M
Source filing
10-Q 4 Jun 2026
Balance sheet
30 Jun 2026

Cash runway

  • 4months

    If the burn speeds up

    Empty by Oct 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$8.9M

÷

Cash burned over the last 12 months

$21.3M

What Greenwich Lifesciences told the SEC

…normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the…

GREENWICH LIFESCIENCES, INC., Form 10-Q, filed 4 Jun 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is increasing It is spending 61% more cash per year than it was, so the runway above shortens even if nothing else changes.
  • Additional financing required It has said it cannot continue on the cash it holds. More money has to come from a raise, a loan or a sale.
  • 10.6% share-count increase The company issued stock. Each share now owns 9.6% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt